Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218127
Title: A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma
Author: Mozas, Pablo
Casanueva Eliceiry, Sebastián
Rivero, Andrea
Serna, Ángel
Simó, Marc
Rodríguez, Sara
Rivas Delgado, Alfredo
Nadeu, Ferran
Correa, Juan Gonzalo
Piñeyroa, Juan Antonio
Pérez Valencia, Amanda Isabel
Guinetti Ortiz, Katia
Gómez Hernando, Marta
Giné, Eva
Delgado González, Julio
Villamor i Casas, Neus
Campo, Elías
Magnano, Laura
Abrisqueta Costa, Pau
Setoain Perego, Xavier
López Guillermo, Armando
Keywords: Limfomes
Tomografia
Tumors
Lymphomas
Tomography
Tumors
Issue Date: 1-Jan-2024
Publisher: John Wiley & Sons
Abstract: Watchful waiting is an acceptable management strategy for advanced-stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment-free observation period will last remains imperfect. We explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters were predictive of time to first treatment (TTFT). We analyzed 97 grade 1-3A advanced-stage LTB FL patients and found that a high TMTV was associated with other tumor burden features at diagnosis. Patients with a TMTV above our established cutoff of 50 mL had a significantly shorter median duration of observation (2.6 vs. 8.8 years; p = 0.001). At 5 years, 77% of patients with a high TMTV and 46% of patients with a low TMTV required treatment. In the multivariable analysis, a high TMTV was the only independent factor predicting TTFT (hazard ratio = 2.09; p = 0.017). Overall, TMTV is a strong predictor of the duration of observation in LTB FL patients. Upon validation of our cutoff in external series and standardization of the methodology, the TMTV could become an additional factor to consider deferring or initiating treatment in otherwise LTB patients.
Note: Reproducció del document publicat a: https://doi.org/10.1002/hon.3235
It is part of: Hematological Oncology, 2024, vol. 42, num.1
URI: https://hdl.handle.net/2445/218127
Related resource: https://doi.org/10.1002/hon.3235
ISSN: 0278-0232
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
870375.pdf641.7 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons